Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

References

• National Osteoporosis Foundation (NOF). Physician’s guide to prevention and treatment of osteoporosis [online]. Available from: http://www.nof.org//physguide/risk_assessment.htm: [accessed 20 April 2004]
   Google Scholar
• National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases. NIH consensus statement – osteoporosis prevention, diagnosis, and therapy. March 27–29, 2000; available from: http://consensus.nih.gov/cons/111/111_statement.htm. [accessed 20 April 2004]
   Google Scholar
• Walker-Bone K, Dennison E, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2001;27:1–18
   PubMed Web of Science ®Google Scholar
• Cranney A, Welch V, Tugwell P, et al. Responsiveness of endpoints in osteoporosis clinical trials – an update. J Rheumatol 1999;26:222–8
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508–16
   Google Scholar
• Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517–23
   Google Scholar
• Fosamax® (alendronate sodium) Prescribing Information. Physicians’ desk reference, 56th ed. Montvale (NJ): Medical Economics Company Inc.; 2002. p. 2095–202
   Google Scholar
• Actonel® (risedronate sodium) Prescribing Information. Physicians’ desk reference, 56th ed. Montvale (NJ): Medical Economics Company Inc.; 2002. p. 2879–84
   Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial [FIT Research Group]. J Clin Endocrinol Metab 2000;85:4118–24
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis [Alendronate Once-Weekly Study Group]. Aging (Milano) 2000;12:1–12
   PubMedGoogle Scholar
• Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103–11
   PubMed Web of Science ®Google Scholar
• Marcus R, Wong M, Heath H 3rd, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002;23: 16–37
   Google Scholar
• McAlister FA, Laupacis A, Wells GA, Sackett DL. Users’ guides to the medical literature: XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. J Am Med Assoc 1999;282:1371–7
   Google Scholar
• Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users’ guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points [Evidence-Based Medicine Working Group]. J Am Med Assoc 1999;282:771–8
   Google Scholar
• Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003;19:383–94
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Hochberg M, Bonnick S, et al. Treatment with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized, double-blind study. J Bone Miner Res [published online 9/29/2004 on WebFirst (no doi number)]
   Google Scholar
• Bonnick SL, Johnston Jr CC, Kleerekoper M, et al. Importance of precision in bone density measurements. J Clin Densitom 2001;4:105–10
   PubMed Web of Science ®Google Scholar
• Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003;32:83–113
   PubMed Web of Science ®Google Scholar
• Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. Use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000;(Suppl 6):S2–17
   Google Scholar
• Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231–6
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis [Fracture Intervention Trial Research Group]. Arthritis Rheum 1999;42:1246–54
   PubMed Web of Science ®Google Scholar
• Freedman DA, Klein SP, Ostland M, Roberts MR. A solution to the ecological inference problem. J Am Stat Assoc 1998;93:1518–22
   Google Scholar
• Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004;7:255–61
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom 2003;6:307–14
   PubMed Web of Science ®Google Scholar
• Pavlic M, Brand RJ, Cummings SR. Estimating probability of non-response to treatment using mixture distributions. Stat Med 2001;20:1739–53
   Google Scholar
• Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84:2363–8
   PubMed Web of Science ®Google Scholar
• Ravn P, Clemmeson B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women [Alendronate Osteoporosis Prevention Study Group]. Bone 1999;24:237–44
   Google Scholar
• Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250–8
   PubMed Web of Science ®Google Scholar
• Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15:613–20
   PubMed Web of Science ®Google Scholar
• Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051–6
   PubMed Web of Science ®Google Scholar
• Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20(8) [doi:10.1185/030079904125004475]
   Google Scholar
• Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189–99
   PubMed Web of Science ®Google Scholar
• Sorensen O, Goemare S, Wenderoth D, Chines A, Roux C. Sustained effect of risedronate: a 7-year study in postmenopausal women. Calcif Tissue Int 2003;72: 402
   Google Scholar
• Carmona RH. Bone health and osteoporosis: a report of the Surgeon General (2004); United States Department of Health and Human Services 2004; Available from: www.hhs.gov/surgeongeneral/library/bonehealth/content.html [accessed on 4 Nov 2004]
   Google Scholar